Five years after the last study participant is randomized, participants who have received an infusion of KITE-363 will transition to a separate Long-term Follow-up study (study KT-US-982-5968) to complete the remainder of the 15-year follow-up assessments.
The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-363, in participants with relapsed and/or refractory B-cell lymphoma.